Gottlieb, Marks Explore Regulatory Pathways for Stem-Cell Development

Drug Industry Daily
The FDA plans to make tools available to provide incentives for doctors or physician groups to collaborate on stem-cell and regenerative medicine products, eventually leading to a biologics license for each doctor or group, CBER Director Peter Marks and Commissioner Scott Gottlieb said in a New England Journal of Medicine article published Thursday.

To View This Article:


Subscribe To Drug Industry Daily